On August 5, 2025, Imunon, Inc. (IMNN) announced financial results for the second quarter of 2025 and provided a business update. The company recently announced the first patient was dosed in the Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer. Three trial sites have been activated thus far, with additional sites, including many from the prior OVATION studies, in the process of being activated. The company has a goal of activating 20 sites by the end of 2025. The OVATION 3 trial includes two interim analyses and is powered at 95% for overall survival improvement, the primary endpoint, in the intent-to-treat population and 99% in the HRD-positive subgroup. To help bolster its balance sheet, Imunon raised more than $3 million following the end of the second quarter of 2025 through warrant exercises and ATM sales. In addition, the company has streamlined operations to help conserve cash, including reductions in G&A expenses and non-core activities.
